China SXT Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for China SXT Pharmaceuticals, Inc. (SXTC) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec 2025Mar 2024Mar 2023Mar 2022Mar 2021
Operating Activities
Net Income-3.30-3.10-5.93-5.74-2.75
Depreciation & Amortization0.080.200.250.320.35
Deferred Income Tax0.000.000.000.330.00
Stock Based Compensation0.000.350.552.330.00
Change in Working Capital-0.97-0.381.421.90-1.61
Change in Accounts Receivable-0.48-0.320.910.83-0.52
Change in Inventory-0.01-0.220.41-0.18-0.30
Change in Accounts Payable-0.11-0.030.04-0.05-0.62
Change in Other Working Capital-0.360.360.410.59-0.26
Other Operating Activities1.850.360.410.590.37
Net Cash from Operating Activities-2.35-1.93-0.080.27-1.32
Investing Activities
Capital Expenditures0.00-0.01-0.07-0.06-0.09
Purchases of Investments0.000.000.000.00-8.85
Other Investing Activities0.070.030.060.023.13
Net Cash from Investing Activities0.060.03-0.01-0.05-5.81
Financing Activities
Debt Repayment-0.07-0.08-0.03-0.03-0.12
Common Stock Issued2.760.002.193.120.00
Other Financing Activities5.70-4.04-3.26-4.260.00
Net Cash from Financing Activities8.40-2.622.941.6012.41
Summary
Effect of Forex Changes on Cash-0.07-0.77-1.050.390.00
Net Change in Cash6.05-4.532.851.826.07
Cash at Beginning of Period12.0817.3715.5713.360.00
Cash at End of Period18.1312.0817.3715.570.00
Free Cash Flow-2.35-1.94-0.150.21-1.41
Supplemental Disclosures
Interest Paid0.020.020.010.000.01
Income Taxes Paid0.000.000.000.020.00